Boston, MA., Nov. 7, 2007 /PRNewswire/- /- Vital Therapies, Inc. (VTI), announced today data from two studies of the company’s ELAD® (Extracorporeal Liver Assist Device) System were presented at the 2007 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, which

Program Expands on Successful Results from prior U.S., U.K. and China Trials

Doctors test latest attempt at artificial liver

Liver device helps man survive until transplant

Vital Therapies Plans Phase III Trials for September

Vital new hope for Liver failure

Pivotal ELAD Study in United States and Europe

Bioartificial Human Liver Therapy Trial Progressing SAN DIEGO , June 8 /PRNewswire/ -- Vital Therapies, Inc., (VTI) is pleased to announce that the first two subjects have been enrolled at King's College Hospital in London in the expansion of its SILVER ( S tabilization I n L i VER failure)

Vital Therapies Expands SILVER Trial to Saudi Arabia

Three-year follow-up data confirm safety and survival benefit in Chinese liver failure patients treated with ELAD ®